Eli Lilly is preparing its next major strategic move in the lucrative obesity treatment market. The company’s management provided a clearer timeline for its oral therapy, orforglipron, during a presentation at the TD Cowen Health Care Conference this week. According to Chief Financial Officer Lucas Montarce, a U.S. launch could occur “as early as the second quarter of 2026,” pending regulatory approval. He emphasized the company’s readiness to move swiftly into commercialization following a potential green light.
This oral alternative is seen as the next growth driver, designed to build on the success of Lilly’s injectable GLP‑1 products. A pill-based treatment is expected to appeal to a broader patient demographic for whom regular injections present a significant barrier.
Navigating Market Access and Pricing Pressures
A significant portion of the discussion focused on market access strategies. Lilly is actively engaged in talks with U.S. Pharmacy Benefit Managers (PBMs) and is working to maximize coverage pathways through Medicare. The company acknowledges that securing favorable reimbursement terms is often the critical factor determining whether a new drug achieves rapid, widespread adoption or becomes entangled in complex coverage negotiations.
Simultaneously, executives addressed industry-wide pricing pressures. Lilly’s stated approach is to counter potential price declines with continued innovation and a significant increase in product volume. The underlying strategy relies on expanding the total patient base and introducing new therapies to offset any pressure on profit margins.
Should investors sell immediately? Or is it worth buying Eli Lilly?
Share Performance and Additional Regulatory News
Despite these strategic updates, Eli Lilly’s stock faced downward pressure on Monday. Reports attributed the decline to a broader market correction, citing geopolitical factors and valuation concerns. Current trading data shows the shares at €869.70, which is below the 50-day moving average of €893.01.
In separate regulatory news from Europe, the company received a positive CHMP recommendation for Olumiant (baricitinib) as a treatment for severe alopecia areata in adolescents. A final decision from the European Commission is anticipated within the next two months. In the United States, Lilly expects a regulatory decision on this same indication in the second half of 2026.
In summary, Eli Lilly continues to execute on multiple fronts to expand its market reach. However, the next major catalyst for the company is closely tied to the regulatory timeline for orforglipron and its subsequent commercial rollout speed in the U.S. market.
Ad
Eli Lilly Stock: Buy or Sell?! New Eli Lilly Analysis from March 3 delivers the answer:
The latest Eli Lilly figures speak for themselves: Urgent action needed for Eli Lilly investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 3.
Eli Lilly: Buy or sell? Read more here...
